Ovavax2
Financiado
Accelerating scale up and commercialisation of 100% bacteria free eggs for use i...
Accelerating scale up and commercialisation of 100% bacteria free eggs for use in production of vaccines
Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world’s first Germ Free egg and bringing it into mass production.
The proposed programme of work will build...
Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world’s first Germ Free egg and bringing it into mass production.
The proposed programme of work will build on the groundwork initiated as part of the 30 month OvaVax project (GA 858390) and provides a logical expansion of this disruptive, innovative technology to the challenges facing the world as it comes to grips with COVID-19 and future pandemics with the need for rapid scale-up of vaccine production
Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2 to expand and accelerate the existing influenza project, to include COVID-19, Yellow Fever, Newcastle Disease and to include readiness for production and accelerated international scaleup of germ free egg production to increase global vaccine manufacturing capacity in readiness for future pandemics similar to COVID-19.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2022-10-26
Fecha Fin: 2024-10-31
Fecha Fin: 2024-10-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
OVAGEN GROUP LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5